Cannabis Law Report

AUGUST 10, 2021

We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Veriheal

MAY 30, 2023

But what if a safe and effective complementary plant-based treatment was widely available to alleviate cancer pain? of patients experience pain after curative treatment, while 66.4% in cancer patients undergoing anticancer treatment, 50.7% in those who had completed treatment, and as high as 66.7%

Medicine 98

Medicine Treatment Patients Data 98

Veriheal

SEPTEMBER 23, 2021

Fortunately, one such man, Levi Barker, provided us with some much-needed insight into what the substance is, how it is used in treatment, and more. I remember that information started spreading through news channels during the 80s. The information was claiming that addiction is a genetic problem. Meet Iboga Expert Levi Barker.

Treatment 98

Treatment Medicine Research and Development Therapy 98

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. Forward-Looking Statements.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Veriheal

NOVEMBER 21, 2023

Quemarr’s transformative approach to diabetes treatment offers patients a less intrusive alternative to conventional insulin treatments. The buddie can be paired with a mobile app that tracks consumption, correlating it with health data from devices like WHOOP, Apple Watch, or Fitbit.

Research and Development 106

Research and Development Consumption Education Data 106

Cannabis Chronicles

MAY 22, 2019

The partnership between the land grant institution in Pullman and the Tacoma-based native tribe is intended to create a standard to evaluate treatment plans at a natural healing clinic the Puyallups opened in October, and to determine the effectiveness of the drug as an alternative to opioids in managing pain.

Medicine 140

Medicine Research and Development Data Collective 140

Cannabis Law Report

NOVEMBER 26, 2019

The FDA also published a revised Consumer Update detailing safety concerns about CBD products more broadly. This includes ongoing work to obtain and evaluate information to address outstanding questions related to the safety of CBD products, while maintaining the agency’s rigorous public health standards.

Safety 64

Safety Food CBD Oil 64

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. Physicians should consider these aspects when advising their patients about treatment with medicinal cannabis.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Veriheal

AUGUST 31, 2022

Harocopos and his team explain that OPCs, also known as supervised/safe consumption sites, are considered to be “health care facilities that aim to improve individual and community health, increase public safety and reduce the consequences of drug use, including overdose deaths, public drug use and syringe litter.” The Research Letter.

Consumption 104

Consumption Data Treatment Collective 104

Cannabis Law Report

JUNE 16, 2021

This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol. Training will be provided within the research program for licensed practitioners to assess the safety of psychedelic medicines and to classify and report positive and adverse events.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Puff Puff Post

MARCH 10, 2020

.” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial. Visit [link].

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

JANUARY 12, 2022

This level of understanding can inform best practices, improve outcomes, and contribute to sensible policy-making both in Oregon and beyond. Through this collaboration, the NPA and Maya will offer both the education and the technology infrastructure needed to make this possible, ensuring accessibility and safety to all communities. “We

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Support for Patient Well-Being The availability of medical marijuana in local communities fosters an environment of support for patients seeking alternative treatments.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. Thus, historical use of cannabis cannot be relied upon in establishing a level of safety for these products in humans.

THC 105

THC Pets Events Hemp 105

Cannabis Law Report

SEPTEMBER 1, 2021

WORCESTER —On the eve of Wednesday, September 1, the Cannabis Control Commission (Commission)’s fourth birthday, adult-use Marijuana Establishments in Massachusetts surpassed $2 billion in gross sales , according to information reported in the state’s mandatory seed-to-sale tracking system, the agency announced today.

Marijuana 100

Marijuana Seed-To-Sale Safety Data 100

Veriheal

AUGUST 7, 2022

New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 billion (USD $2 billion).

Consumption 109

Consumption Patients Research and Development Data 109

Cannabis Law Report

DECEMBER 11, 2021

This reduction in prices will make the clinic the cheapest option for many patients looking to receive medical cannabis treatments for a wide variety of conditions and illnesses. Medical cannabis can be considered as a treatment for a number of conditions – including chronic pain, epilepsy, and insomnia – when first-line options have failed.

Access 52

Access Patients Chronic Pain Treatment 52

Canna Law Blog

APRIL 13, 2019

These products have not been shown to be safe or effective, and deceptive marketing of unproven treatments may keep some patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases.”. Marketing, labeling and sales : How should consumers be informed about the risks associated with such products (e.g.,

CBD 93

CBD Safety Topical Food 93

Otherside Farms

JANUARY 25, 2019

“This meta-analysis of pre-clinical stroke studies provides valuable information on the existing, and importantly, missing data on the use of cannabinoids as a potential treatment for stroke patients. The findings have identified the potential for cannabinoids to reduce brain damage caused by stroke.

Clinical Trials 74

Clinical Trials Marijuana Cannabinoids Data 74

Veriheal

JUNE 30, 2023

Additionally, participants also reported feeling increased self-awareness and general improvement in relationships following their treatment. The 14-page document covers several aspects of the drug development process, including trial best practices, data collection, and new drug application requirements.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

FEBRUARY 15, 2022

The goal is to use the data for comparative analysis over time to help shape state policy. The study uses a wealth of secondary data to provide a snapshot of present-day usage and law-enforcement measures across age, racial, and gender lines. So in order to ameliorate those situations, you need to know all of that other information.”.

Policy 52

Policy Marijuana Data Education 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. On track to report top-line data by end of 2021. Net loss for the six months ended 30 June 2021 was $30.2 million, or $0.79 million) compared with $24.8 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. US Provisional Patent Filed. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects.

Research and Development 108

Research and Development Data THC Clinical Trials 108

The Blunt Truth

AUGUST 13, 2019

On May 31, 2019, the FDA’s Working Group held a public hearing for stakeholders to share their experiences and challenges with CBD products, including information and views related to product safety. The FDA is collecting data to fill these gaps. The public hearing attracted over 100 speakers and 2000 participants.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Veriheal

DECEMBER 23, 2022

Dr. Maxwell’s team also collected data contained in samples sourced from California. After a close analysis of the data, the team determined that an absence of consistent federal guidelines regarding marijuana contaminants ultimately increases the risk of consumers developing health issues.

Research and Development 92

Research and Development Agriculture Data Extraction 92

Cannabis Law Report

SEPTEMBER 29, 2021

With patient safety at the center of its mission, TCI was created to educate healthcare professionals on the risks and benefits of medical cannabis, now legal in the state of New York and beyond. About The Cannabinoid Institute ??

Cannabinoids 52

Cannabinoids Education Patients Safety 52

The Joint Blog

JANUARY 3, 2020

Marijuana-based medicines “might be effective and safe in the treatment of tics and comorbidities” in those with Gilles de la Tourette Syndrome, according to a new study published in the journal Cannabis and Cannabinoids Research and e-published by the National Institute of Health.

Data 49

Data Treatment Marijuana Patients 49

Cannabis Law Report

JULY 29, 2021

Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. For more information visit: www.tetrabiopharma.com.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

MMJ Recs

MARCH 16, 2024

With increasing acceptance of medical marijuana as a legitimate treatment option for various health conditions, the industry has attracted significant attention from investors, entrepreneurs, and policymakers alike. Policy decisions related to taxation, zoning, and advertising also impact the industry’s operations and growth trajectory.

Supply Chain 105

Supply Chain Research and Development Marijuana Seed-To-Sale 105

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. CBG, however, also has some medicinal potential that CBD doesn’t, for instance as a treatment for hypertension and insulin resistance. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

AUGUST 16, 2021

The registry is a clearinghouse of reports related to child abuse and neglect, and the information may be used for purposes including determination qualifications for persons employed in positions providing service to children or vulnerable adults. At the end of May 2019, DCS informed the new mother that she was being placed on the registry.

Safety 116

Safety Patients Cannabis Law 116

Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease. For more information visit: [link]. Orphan Drug Designation? 561-627-9455.

DEA 66

DEA Clinical Trials THC Research and Development 66

Puff Puff Post

MARCH 10, 2020

.” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial. Visit [link].

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Illinois News Joint

APRIL 2, 2023

C) 25% shall be transferred to the Criminal Justice Information Projects Fund to be used for the purposes of the Restore, Reinvest, and Renew Program to address economic development, violence prevention services, re-entry services, youth development, and civil legal aid, as defined by Section 15 of the Public Interest Attorney Assistance Act.

Education 89

Education Cannabis Collective Programs 89